Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp

Trial Profile

A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs KX 01 (Primary)
  • Indications Actinic keratosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Athenex
  • Most Recent Events

    • 04 Feb 2019 According to an Athenex media release, the results from two phase III studies (KX01-AK-003 and KX01-AK-004) has been accepted and will be presented at the Late-Breaking Research Program at the 2019 American Academy of Dermatology Annual Meeting (March 1-5, 2019).
    • 20 Nov 2018 Planned primary completion date changed from 29 Jun 2018 to 1 Apr 2019.
    • 14 Nov 2018 According to an Athenex media release, the company has announced positive data from this study. The follow up data from this study is expected in the second quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top